Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial

Simply Wall St.04-11

ORIC Pharmaceuticals recently reported updated Phase 1b data for its PRC2 inhibitor rinzimetostat (ORIC-944) combined with darolutamide in previously treated metastatic castration-resistant prostate ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626128170?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-11 15:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626128170","market":"nz","top_or_hot":-1,"title":"Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial","media":"Simply Wall St.","content":"<div>\n<p>ORIC Pharmaceuticals recently reported updated Phase 1b data for its PRC2 inhibitor rinzimetostat (ORIC-944) combined with darolutamide in previously treated metastatic castration-resistant prostate ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/why-oric-pharmaceuticals-oric-is-up-142-after-advancing-rinz\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy ORIC Pharmaceuticals (ORIC) Is Up 14.2% After Advancing Rinzimetostat Combo Into Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-11 15:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/why-oric-pharmaceuticals-oric-is-up-142-after-advancing-rinz><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ORIC Pharmaceuticals recently reported updated Phase 1b data for its PRC2 inhibitor rinzimetostat (ORIC-944) combined with darolutamide in previously treated metastatic castration-resistant prostate ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/why-oric-pharmaceuticals-oric-is-up-142-after-advancing-rinz\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ORIC","symbol_name":"Oric Pharmaceuticals Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/why-oric-pharmaceuticals-oric-is-up-142-after-advancing-rinz","article_id":"2626128170","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-oric/oric-pharmaceuticals/news/why-oric-pharmaceuticals-oric-is-up-142-after-advancing-rinz","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2626128170","pubTimestamp":1775892655,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ORIC Pharmaceuticals recently reported updated Phase 1b data for its PRC2 inhibitor rinzimetostat (ORIC-944) combined with darolutamide in previously treated metastatic castration-resistant prostate cancer, selecting a 400 mg once-daily regimen as the recommended Phase 3 dose based on efficacy and safety analyses.\nThe company now plans a large global Phase 3 registrational trial targeting an addressable mCRPC market it estimates at over US$3.50 billions in the US and US$7.00 billions...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ORIC":"Oric Pharmaceuticals Inc.","BK4139":"生物科技"},"translate_title":"为什么ORIC Pharmaceuticals(ORIC)在将Rinzimetostat组合推进至3期试验后股价上涨14.2%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORIC":1.5},"content_text":"ORIC Pharmaceuticals recently reported updated Phase 1b data for its PRC2 inhibitor rinzimetostat (ORIC-944) combined with darolutamide in previously treated metastatic castration-resistant prostate cancer, selecting a 400 mg once-daily regimen as the recommended Phase 3 dose based on efficacy and safety analyses. The company now plans a large global Phase 3 registrational trial targeting an addressable mCRPC market it estimates at over US$3.50 billions in the US and US$7.00 billions worldwide, where there is a gap for oral therapies that balance meaningful efficacy with a favorable tolerability profile. Next, we will examine how the Phase 3 move for rinzimetostat plus darolutamide, backed by encouraging early efficacy, shapes ORIC’s investment narrative. AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementWhat Is ORIC Pharmaceuticals' Investment Narrative?For ORIC to make sense as a holding, you have to buy into a pure drug‑development story where rinzimetostat plus darolutamide is the central asset, not a side bet. The new Phase 1b update sharpens that narrative: a clear 400 mg once‑daily dose, encouraging early efficacy, and a safety profile that appears well suited to a chronic oral regimen all help de‑risk the design of the upcoming Himalayas‑1 Phase 3 trial. That raises the importance of trial execution, regulatory dialogue and future financing as the key near‑term catalysts, rather than quarterly numbers from a company with no revenue and ongoing losses. At the same time, the stock’s sharp 1‑year move, continued volatility and recent dilution keep funding risk and downside volatility very much in focus, even with this stronger dataset. However, there is a funding and dilution risk here that investors should understand.\n\nORIC Pharmaceuticals' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesORIC 1-Year Stock Price Chart The Simply Wall St Community’s two fair value views span roughly US$21 to about US$43, underscoring how far apart expectations can sit. Set that against ORIC’s cash burn and reliance on successful Phase 3 execution, and it becomes clear why considering multiple viewpoints on risk and reward is essential.Explore 2 other fair value estimates on ORIC Pharmaceuticals - why the stock might be worth just $21.00!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your ORIC Pharmaceuticals research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.Our free ORIC Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ORIC Pharmaceuticals' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626128170","isCrawlerRequest":true}